Proteins and Peptides
3 October 2014
APT Therapeutics’ Apyrase-Based Investigational Drug Minimizes Damage from Heart Attack without Increasing Hemorrhage2 October 2014
Revance Therapeutics Provides Update on RT001 Clinical Program for the Lead Indication for Crow’s Feet Lines1 October 2014
ERYTECH Reports Positive Top-Line Phase III Results from Clinical Study with GRASPA® in Acute Lymphoblastic Leukemia26 September 2014
Novartis drug Signifor® LAR recommended by CHMP for EU approval to treat patients with rare hormonal disorder acromegaly26 September 2014
Approval for Sustained-Duration G-CSF Product G-Lasta® in Japan25 September 2014
Celldex Therapeutics Initiates Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Transplantation25 September 2014
Blaze Bioscience Announces Initiation of Phase 1b Brain Cancer Program for Tumor PaintTM BLZ-10023 September 2014
Novaliq GmbH Reports Positive Results from CyclASol® (Cyclosporin Solution) Eye Drops Repeated and Ascending Dose Phase 1 Study22 September 2014
New Xultophy® (IDegLira) data show rapid and predictable glycaemic improvements in people with type 2 diabetes22 September 2014
Novo Nordisk – Xultophy® (IDegLira) approved in Europe19 September 2014
Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes19 September 2014
Paediatric Patients with Hypophosphatasia Receiving Investigational Asfotase Alfa Had Sustained Improvements in Growth and Physical Function18 September 2014
Ryzodeg® provides successful glycaemic control with fewer injections than a basal-bolus regimen18 September 2014
biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation18 September 2014
SWOG To Resume Clinical Trial Of Halozyme’s PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer16 September 2014
Mylan Commences Phase III Clinical Trials for its Generic Version of Advair Diskus® and Insulin Analog to Lantus16 September 2014
CSL Behring Announces Last Patient Treated in Phase III Study of Fibrinogen Concentrate to Control Bleeding During Aortic Aneurysm Surgery16 September 2014
Thrasos Announces Successful Formal Interim Analysis and Clinical Update for Phase 2 Study of THR-184 for Acute Kidney Injury15 September 2014
Ultragenyx Announces Positive Results From a Long-Term Phase 1/2 Study of KRN23 in Adult Patients With X-Linked Hypophosphatemia15 September 2014
FDA Approves Baxter’s RIXUBIS [Coagulation Factor IX (Recombinant)] for Treatment of Children with Hemophilia B13 September 2014
FDA Advisory Committee Recommends Approval of Natpara® for Long-Term Treatment of Hypoparathyroidism13 September 2014
Novartis demonstrates leadership in ophthalmology with new products and over 40 abstracts at EURETINANews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports